Non-alcoholic fatty liver disease (NAFLD) typically exists in a milieu of disturbed
metabolism, including increased total body adiposity, insulin resistance, impaired
glucose tolerance and dyslipidemia [
[1]
]. Cumulatively, these factors increase the risk for cardiovascular disease (CVD),
and so it is not surprising that CVD is the leading cause of death in NAFLD patients
[
[2]
]. The challenge over the past decade has been to tease apart the complex and inter-dependent
relationships between NAFLD and these etiological factors, to establish whether NAFLD
per se increases the risk of developing CVD. The validation of NAFLD as a significant additional
risk factor would have direct relevance for primary preventative strategies against
CVD.Abbreviations:
NAFLD (non-alcoholic fatty liver disease), CVD (cardiovascular disease), cIMT (carotid intimal media thickness), FLI (fatty liver index), GGT (gamma-glutamyl transferase)Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of HepatologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis.Nat Rev Gastroenterol Hepatol. 2013; 10: 330-344
- The natural history of nonalcoholic fatty liver disease: a population-based cohort study.Gastroenterology. 2005; 129: 113-121
- Fatty liver as an independent predictor of early carotid atherosclerosis: results from a large transversal and long-term follow-up.J Hepatol. 2016; 65: 95-102
- Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis.Circulation. 2007; 115: 459-467
- The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population.BMC Gastroenterol. 2006; 6: 33
- External validation of the fatty liver index and lipid accumulation product indices, using 1H-magnetic resonance spectroscopy, to identify hepatic steatosis in healthy controls and obese, insulin-resistant individuals.Eur J Endocrinol. 2014; 171: 561-569
- Nonalcoholic fatty liver disease and vascular function: cross-sectional analysis in the Framingham heart study.Arterioscler Thromb Vasc Biol. 2015; 35: 1284-1291
- Importance of cardiometabolic risk factors in the association between nonalcoholic fatty liver disease and arterial stiffness in adolescents.Hepatology. 2013; 58: 1306-1314
- Association of nonalcoholic fatty liver disease with subclinical myocardial remodeling and dysfunction: A population-based study.Hepatology. 2015; 62: 773-783
- A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care?.Atherosclerosis. 2013; 230: 258-267
- Metabolically normal obese people are protected from adverse effects following weight gain.J Clin Invest. 2015; 125: 787-795
- Systemic complications of nonalcoholic fatty liver disease: when the liver is not an innocent bystander.Semin Liver Dis. 2015; 35: 236-249
- Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States.Hepatology. 2013; 57: 1357-1365
- Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients.Diabetes. 2005; 54: 3541-3546
- Ultrasonographic hepatic steatosis increases prediction of mortality risk from elevated serum gamma-glutamyl transpeptidase levels.Hepatology. 2009; 50: 1403-1411
- Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease.World J Gastroenterol. 2007; 13: 1579-1584
- Fatty liver predicts the risk for cardiovascular events in middle-aged population: a population-based cohort study.BMJ Open. 2014; 4e004973
- TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease.Nat Commun. 2014; 5: 4309
- Systematic evaluation of coding variation identifies a candidate causal variant in TM6SF2 influencing total cholesterol and myocardial infarction risk.Nat Genet. 2014; 46: 345-351
- Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease.Hepatology. 2015; 61: 506-514
- TM6SF2: catch-22 in the fight against nonalcoholic fatty liver disease and cardiovascular disease?.Gastroenterology. 2015; 148: 679-684
- Genetic factors that affect risk of alcoholic and non-alcoholic fatty liver disease.Gastroenterology. 2016; (Feb 9. pii: S0016-5085(16)00138-4; [Epub ahead of print])https://doi.org/10.1053/j.gastro.2016.01.037
- Cardiovascular risk assessment: a global perspective.Nat Rev Cardiol. 2015; 12: 301-311
- The Framingham risk score and heart disease in nonalcoholic fatty liver disease.Liver Int. 2012; 32: 945-950
- NASH resolution is associated with improvements in HDL and triglyceride levels but not improvement in LDL or non-HDL-C levels.Aliment Pharmacol Ther. 2015; 41: 301-309
Article info
Publication history
Published online: March 26, 2016
Accepted:
March 20,
2016
Received:
March 17,
2016
See Article, pages 95–102Identification
Copyright
© 2016 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
